Istituto Clinico Humanitas

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

46/100

Pipeline Velocity

22/100

Trial Completion Rate

86/100

Pipeline Concentration

100/100

Pipeline Freshness

33/100

Activity

Key Events

Aug 28, 2026TrialPhoton-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis

Jul 29, 2026TrialPhoton-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM

Jul 8, 2026TrialAdvanced Respiratory Monitoring for Safer Mechanical Ventilation in Patients Without Respiratory Failure

Jun 26, 2026TrialIntra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. A Prospective Multicenter Observational Study

Jun 26, 2026TrialRIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery (the RIVER-2 Study)

Jun 25, 2026TrialThe Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome: a Randomized Clinical Trial Within an Adaptive Platform Trial for Patients With Bloodstream Infections

Mar 25, 2026TrialMulticenter Retrospective International Study to Evaluate Outcomes and Safety of Patients Undergoing ERCP Using a Single-use Cholangioscope (SpyGlass DS II) and Single-use Duodenoscope (Exalt) - The MESE Study

Feb 9, 2026FDAReglan — REGLAN

4 more events

Jun 16, 2023TrialStudy of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Dec 13, 2022TrialEvaluation Study of the Intestinal Microbiota and Quality of Life in Patients Suffering From IBS Treated With Bifidice

Dec 1, 2022TrialEvaluation of Efficacy, Safety and Patient' Satisfaction of Therapeutic Switch From Off-Steroids to Budesonide

Dec 3, 2021TrialAnti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

6 patent groups across drugs · Source: FDA Orange Book

DrugExpires

VeregenOct 2, 2026 Reglan5 patentsDec 22, 2029 ReglanMay 16, 2030 ReglanNov 17, 2038 ActhJul 18, 2041 Acth5 patentsOct 27, 2043

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Prostate Cancer

immune evaluation

Oncology

Prostate Cancer

immune evaluationPreclinical

Regulatory

Regulatory Timeline

20032 events

FDAApr 22

Reglan — REGLAN

Application NDA017854

FDAApr 22

Reglan — REGLAN

Application NDA017854

20041 event

FDAJul 26

Reglan — REGLAN

Application NDA017854

20052 events

FDAJun 10

Reglan — REGLAN ODT

Application NDA021793 (NDA)

FDAJun 10

Reglan — REGLAN ODT

Application NDA021793 (NDA)

20061 event

FDAOct 31

Veregen — VEREGEN

Application NDA021902 (NDA)

20094 events

FDASep 4

Reglan — METOZOLV ODT

Application NDA022246 (NDA)

FDASep 4

Reglan — METOZOLV ODT

Application NDA022246 (NDA)

FDASep 4

Reglan — REGLAN

Application NDA017854

FDAJun 30

Reglan — REGLAN

Application NDA017854

20101 event

FDANov 18

Reglan — REGLAN

Application NDA017854

20112 events

FDASep 22

Reglan — REGLAN

Application NDA017854

FDAAug 2

Reglan — REGLAN

Application NDA017854

20153 events

FDAJun 15

Reglan — REGLAN

Application NDA017854

FDAApr 17

Reglan — REGLAN

Application NDA017854

FDAJan 12

Reglan — REGLAN

Application NDA017854

20171 event

FDAAug 29

Reglan — REGLAN

Application NDA017854

20202 events

FDAJun 19

Reglan — GIMOTI

Application NDA209388 (NDA)

FDAJun 19

Reglan — GIMOTI

Application NDA209388 (NDA)

20261 event

FDAFeb 9

Reglan — REGLAN

Application NDA017854

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)